Form D · Biotechnology
Uvantis Therapeutics, Inc.
Columbia, MD · CIK 0002156954
Offering snapshot reported Sep 23, 2026 · SEC filing
- Reported sold
- $100K Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 23, 2026 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598636
Source: Form D, filed Sep 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Collins | Executive |
| Paul Giannasca | Executive |
| William Sheahan | Director |
| Edward Woo | Director |
| Jonathan Young | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10980 Grantchester Way
Columbia, MD, 21044
Phone: 6174176695
Columbia, MD, 21044
Phone: 6174176695